SP Industries acquires PennTech Machinery Corporation
Penntech is a global provider of complete vial handling solutions covering washing, sterilization, filling, stoppering, capping and both tray and freeze dryer loading/unloading equipment.
SP Industries, a leading designer and manufacturer of state-of-the-art laboratory equipment, research, pilot and production freeze dryers, laboratory supplies and glassware has acquired the assets of privately held PennTech Machinery Corporation.
Penntech is a global provider of complete vial handling solutions covering washing, sterilization, filling, stoppering, capping and both tray and freeze dryer loading/unloading equipment, located in Warminster (PA, USA).
“PennTech has a well-earned reputation for producing high quality, often customized, equipment and is the only US-based manufacturer to offer complete aseptic processing lines,” stated SP CEO Bill Downs. “As a leading supplier to the pharmaceutical, biotech and scientific markets, SP is continually focused on bringing value to our customer relationships. PennTech’s current portfolio, engineering expertise and broad capabilities around liquid vial handling are a very strategic complement to our Hull and VirTis pilot and production freeze dryer lines, allowing us to offer a complete suite of manufacturing solutions for semi-automated to fully automated drug production environments.”
Downs continued by saying: “We are excited to establish PennTech as a flagship brand within our SP Scientific equipment division. Key manufacturing, engineering, sales and service personnel from PennTech have joined the SP team to assure continuity in operations and service. Vincent Smit, who had served as CEO of PennTech, will play a significant role in sales and product development projects and we look forward to benefiting from his vision and depth of knowledge.“
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.